{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:49:08Z","timestamp":1763012948618,"version":"3.45.0"},"reference-count":25,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,5,15]]},"DOI":"10.1080\/14796694.2025.2491297","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T07:45:26Z","timestamp":1746603926000},"page":"1511-1523","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study"],"prefix":"10.1080","volume":"21","author":[{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"first","affiliation":[{"name":"Istanbul University\u2212Cerrahpa\u015fa","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer & Hematology Centers of Western Michigan","place":["Grand Rapids, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nenad","family":"Medic","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Cambridge, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Mann","sequence":"additional","affiliation":[{"name":"Oncology Biometrics, AstraZeneca, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Chugh","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapashi","family":"Dalvi","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Universidad Complutense and Ciberonc","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00339"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.003"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0911494"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3332"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05928-4"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr485"},{"key":"e_1_3_8_12_1","unstructured":"US National Cancer Institute (NCI). Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u00ae) [internet]. cited 2025 Jan 10: Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159514"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.009"},{"key":"e_1_3_8_15_1","unstructured":"US Food and Drug Administration (FDA). Project patient voice [internet]. cited 2025 Jan 10: Available from: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-patient-voice"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.003"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00118"},{"key":"e_1_3_8_18_1","unstructured":"JAMA Network. Instructions for authors: how do I? Determine my study type [internet]. cited 2025 Jan 10: Available from: https:\/\/jamanetwork.com\/journals\/jama\/pages\/instructions-for-authors#SecStudyTypeSurveyStudy"},{"key":"e_1_3_8_19_1","volume-title":"Poster presented at: American Society of Clinical Oncology Annual meeting","author":"\u00d6zg\u00fcro\u011flu M","year":"2022","unstructured":"\u00d6zg\u00fcro\u011flu M, Goldman JW, Chen Y, et al. Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study. In: Poster presented at: American Society of Clinical Oncology Annual meeting; Chicago, IL; 2022 Jun 3\u20137."},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07779-3"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3297-9"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp386"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02558-7"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00210-z"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.026"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774520975120"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.38"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2491297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:45:36Z","timestamp":1763012736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2491297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,5,15]]}},"alternative-id":["10.1080\/14796694.2025.2491297"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2491297","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}